Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human cancers. Actually, ATC is refractory to conventional therapies, including surgery, chemotherapy, radiotherapy, and radioiodine (131I) therapy. Accordingly, genetic and molecular characterizations of ATC have been frequently and p...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2014/685396 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558501465948160 |
|---|---|
| author | Rosalba Parenti Lucia Salvatorelli Gaetano Magro |
| author_facet | Rosalba Parenti Lucia Salvatorelli Gaetano Magro |
| author_sort | Rosalba Parenti |
| collection | DOAJ |
| description | Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human cancers. Actually, ATC is refractory to conventional therapies, including surgery, chemotherapy, radiotherapy, and radioiodine (131I) therapy. Accordingly, genetic and molecular characterizations of ATC have been frequently and periodically reviewed in order to identify potential biological markers exploitable for target therapy. This review briefly focuses on main molecular events that characterize ATC and provides an update about preclinical studies. In addition, the overexpression of transferrin receptor 1 (TfR1/CD71) by neoplastic cells of ATC is emphasized in that it could represent a potential therapeutic target. In this regard, new therapeutic approaches based on the use of monoclonal or recombinant antibodies, or transferrin-gallium-TfR1/CD71 molecular complexes, or lastly small interfering RNAs (siRNAs) are proposed. |
| format | Article |
| id | doaj-art-157b4c926d7e4d3182d2d4df6dc184f3 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-157b4c926d7e4d3182d2d4df6dc184f32025-02-03T01:32:06ZengWileyInternational Journal of Endocrinology1687-83371687-83452014-01-01201410.1155/2014/685396685396Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71Rosalba Parenti0Lucia Salvatorelli1Gaetano Magro2Department of Bio-Medical Sciences, Physiology Section, University of Catania, Viale A. Doria 6, 95125 Catania, ItalyDepartment G.F. Ingrassia, Section of Anatomic Pathology, University of Catania, Via S. Sofia 87, 95123 Catania, ItalyDepartment G.F. Ingrassia, Section of Anatomic Pathology, University of Catania, Via S. Sofia 87, 95123 Catania, ItalyAnaplastic thyroid carcinoma (ATC) is one of the most aggressive human cancers. Actually, ATC is refractory to conventional therapies, including surgery, chemotherapy, radiotherapy, and radioiodine (131I) therapy. Accordingly, genetic and molecular characterizations of ATC have been frequently and periodically reviewed in order to identify potential biological markers exploitable for target therapy. This review briefly focuses on main molecular events that characterize ATC and provides an update about preclinical studies. In addition, the overexpression of transferrin receptor 1 (TfR1/CD71) by neoplastic cells of ATC is emphasized in that it could represent a potential therapeutic target. In this regard, new therapeutic approaches based on the use of monoclonal or recombinant antibodies, or transferrin-gallium-TfR1/CD71 molecular complexes, or lastly small interfering RNAs (siRNAs) are proposed.http://dx.doi.org/10.1155/2014/685396 |
| spellingShingle | Rosalba Parenti Lucia Salvatorelli Gaetano Magro Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71 International Journal of Endocrinology |
| title | Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71 |
| title_full | Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71 |
| title_fullStr | Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71 |
| title_full_unstemmed | Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71 |
| title_short | Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71 |
| title_sort | anaplastic thyroid carcinoma current treatments and potential new therapeutic options with emphasis on tfr1 cd71 |
| url | http://dx.doi.org/10.1155/2014/685396 |
| work_keys_str_mv | AT rosalbaparenti anaplasticthyroidcarcinomacurrenttreatmentsandpotentialnewtherapeuticoptionswithemphasisontfr1cd71 AT luciasalvatorelli anaplasticthyroidcarcinomacurrenttreatmentsandpotentialnewtherapeuticoptionswithemphasisontfr1cd71 AT gaetanomagro anaplasticthyroidcarcinomacurrenttreatmentsandpotentialnewtherapeuticoptionswithemphasisontfr1cd71 |